AblaCor™ Medical Corporation, with an exceptional team of business and technical professionals and endorsement from prominent electrophysiologists and cardiologists, is developing a game-changing, platform technology for the treatment of atrial fibrillation (AF). The company’s first product, the CircumBlator™, is designed to fundamentally improve the treatment for millions of untreated and under-treated patients with atrial fibrillation (AF). The cause of approximately 20 percent of strokes, AF treatment costs are estimated to be $26 Billion annually in the US alone. A cornerstone of all catheter ablation procedures, pulmonary vein isolation (PVI) is a key treatment for patients with AF. The CircumBlator is the first ablation system that will eliminate significant procedural difficulties that occur during PVI procedures when performed with ablation catheters on the market today.
Introduction video to AblaCor and the CircumBlator
Click play above to hear AblaCor CEO Martin Sklar's interview on Radio Entrepreneurs
Content copyright . ABLACOR.COM. All rights reserved.